tbuckley/cabot-search huggingface dataset:
Abstract P3-03-36: Not presented
Authors: RN Khan, M Baig, S Mohtasham, A Khan, A Pervaiz
Journal: Cancer Research (2019)

Abstract This abstract was not presented at the conference. Citation Format: Khan RN, Baig M, Mohtasham S, Khan A, Pervaiz A. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-36.
Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration
Authors: Deborah M. Stephens, Ken Boucher, Elizabeth Kander, Sameer A. Parikh, Erin Parry, Mazyar Shadman, John M. Pagel, Jennifer Cooperrider, Joanna Rhodes, Anthony R. Mato, Allison M. Winter, Brian T. Hill, Sameh Gaballa, Alexey V Danilov, Tycel J. Phillips, Danielle M. Brander, Sonali M. Smith, Matthew S Davids, Kerry A. Rogers, Martha Glenn, John C. Byrd
Journal: Blood (2018)
Organ donation: England’s opt-out system could save 700 lives a year
Authors: Clare Dyer
Journal: BMJ (2019)

England will have an opt-out system for organ donation from spring 2020, after a bill to implement the change passed its final stage in the UK parliament this week.

The Organ Donation (Deemed Consent) Bill passed its third reading in the House of Lords, the final hurdle before royal assent. When the law comes into force all people in England will be presumed to consent to donating their organs unless they register their decision to opt out.

The UK government believes that the change in …
Eye-Tracking Test Approved to Help Diagnose Concussion
Authors: Rebecca Voelker
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma
Authors: Thomas E. Merchant, Anne E. Bendel, Noah D. Sabin, Peter C. Burger, Dennis W. Shaw, Eric Chang, Shengjie Wu, Tianni Zhou, David D. Eisenstat, Nicholas K. Foreman, Christine E. Fuller, Edwina Templeton Anderson, Juliette Hukin, Ching C. Lau, Ian F. Pollack, Fred H. Laningham, Robert H. Lustig, Floyd D. Armstrong, Michael H. Handler, Chris Williams-Hughes, Sandra Kessel, Mehmet Kocak, David W. Ellison, Vijay Ramaswamy
Journal: Journal of Clinical Oncology (2019)

The Children's Oncology Group trial ACNS0121 estimated event-free survival (EFS) and overall survival for children with intracranial ependymoma treated with surgery, radiation therapy, and-selectively-with chemotherapy. Treatment was administered according to tumor location, histologic grade, and extent of resection. The impacts of histologic grade, focal copy number gain on chromosome 1q, and DNA methylation profiles were studied for those undergoing surgery and immediate postoperative conformal radiation therapy (CRT).ACNS0121 included 356 newly diagnosed patients (ages 1 to 21 years). Patients with classic supratentorial ependymoma were observed after gross total resection (GTR). Those undergoing subtotal resection received chemotherapy, second surgery, and CRT. The remaining patients received immediate postoperative CRT after near-total resection or GTR. CRT was administered with a 1.0-cm clinical target volume margin. The cumulative total dose was 59.4 Gy, except for patients who underwent GTR and were younger than age 18 months (who received 54 Gy). Patients were enrolled between October 2003 and September 2007 and were observed for 5 years. Supratentorial tumors were evaluated for RELA fusion; infratentorial tumors, for chromosome 1q gain. Classification of posterior fossa groups A and B was made by methylation profiles.The 5-year EFS rates were 61.4% (95% CI, 34.5% to 89.6%), 37.2% (95% CI, 24.8% to 49.6%), and 68.5% (95% CI, 62.8% to 74.2%) for observation, subtotal resection, and near-total resection/GTR groups given immediate postoperative CRT, respectively. The 5-year EFS rates differed significantly by tumor grade (P = .0044) but not by age, location, RELA fusion status, or posterior fossa A/posterior fossa B grouping. EFS was higher for patients with infratentorial tumors without 1q gain than with 1q gain (82.8% [95% CI, 74.4% to 91.2%] v 47.4% [95% CI, 26.0% to 68.8%]; P = .0013).The EFS for patients with ependymoma younger than 3 years of age who received immediate postoperative CRT and for older patients is similar. Irradiation should remain the mainstay of care for most subtypes.
Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Western Pacific Region, 2005–2017
Authors: Joseph Woodring, Roberta Pastore, Anne Brink, Naoko Ishikawa, Yoshihiro Takashima, Rania A. Tohme
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

Hepatitis B vaccine (HepB), which has been available since 1982, provides lifelong protection against hepatitis B virus (HBV) infection and the associated 20%-30% increased lifetime risk for developing cirrhosis or hepatocellular carcinoma among >95% of vaccine recipients (1). Before HepB introduction into national childhood immunization schedules, the estimated hepatitis B surface antigen (HBsAg) prevalence in the World Health Organization (WHO) Western Pacific Region (WPR)* was >8% in 1990 (2). In 2005, the WPR was the first WHO region to establish a hepatitis B control goal, with an initial target of reducing HBsAg prevalence to <2% among children aged 5 years by 2012. In 2013, the WPR set more stringent control targets to achieve by 2017, including reducing HBsAg prevalence to <1% in children aged 5 years and increasing national coverage with both timely HepB birth dose (HepB-BD) (defined as administration within 24 hours of birth) and the third HepB dose (HepB3) to ≥95% (3). All WPR countries/areas endorsed the Regional Action Plan for Viral Hepatitis in the Western Pacific Region 2016-2020 in 2015 (4) and the Regional Framework for the Triple Elimination of Mother-to-Child Transmission of human immunodeficiency virus (HIV), Hepatitis B and Syphilis in Asia and the Pacific 2018-2030 (triple elimination framework) in 2017 (5). These regional targets and strategies are aligned with program targets established by the WHO Global Health Sector Strategy on Viral Hepatitis 2016-2021 that aim to reduce HBsAg prevalence among children aged 5 years to ≤1% by 2020 and to ≤0.1% by 2030 (6). This report describes progress made to achieve hepatitis B control in the WPR and the steps taken to eliminate mother-to-child transmission (MTCT) of HBV during 2005-2017. During this period, regional timely HepB-BD and HepB3 coverage increased from 63% to 85% and from 76% to 93%, respectively. As of December 2017, 15 (42%) countries/areas achieved ≥95% timely HepB-BD coverage; 18 (50%) reached ≥95% HepB3 coverage; and 19 (53%) countries/areas as well as the region as a whole were verified to have achieved the regional and global target of <1% HBsAg prevalence among children aged 5 years. Continued implementation of proven vaccination strategies will be needed to make further progress toward WPR hepatitis B control targets. In addition to high HepB-BD and HepB3 coverage, enhanced implementation of complementary hepatitis B prevention services through the triple elimination framework, including routine HBsAg testing of pregnant women, timely administration of hepatitis B immunoglobulin to exposed newborns, and antiviral treatment of mothers with high viral loads, will be needed to achieve the global hepatitis B elimination target by 2030.
Fail-Fast in Respiratory Syncytial Virus Vaccine Development
Authors: Sjanna B. Besteman, Louis J. Bont
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

In summary, Owens and coworkers (5) have shown that in utero smoke exposure is associated with PFT deficits later in life.They argue that in utero smoke affects lung size, and that this effect is modulated by antioxidant genotype.Although more studies are needed, this article confirms the value of primary prevention to mitigate the adverse effects of in utero smoke exposure on the sensitive fetal lung.
Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities
Authors: Kinam Park, Andrew Otte
Journal: Annual Review of Biomedical Engineering (2019)

Prescription opioid medications have seen a dramatic rise in misuse and abuse, leading regulators and scientists to develop policies and abuse-deterrent technologies to combat the current opioid epidemic. These abuse-deterrent formulations (ADFs) are intended to deter physical and chemical tampering of opioid-based products, while still providing safe and effective delivery for therapeutic purposes. Even though formulations with varying abuse-deterrent technologies have been approved, questions remain about their effectiveness. While these formulations provide a single means to combat the epidemic, a greater emphasis should be placed on formulations for treatment of addiction and overdose to help those struggling with opioid dependence. This article analyzes various ADFs currently in clinical use and explores potential novel systems for treatment of addiction and prevention of overdose.
TCT-470 Comparison of 5-year Clinical Outcomes between Stabilized Acute Myocardial Infarction Patients following Percutaneous Coronary Intervention and the Patients with Angina Pectoris
Authors: Ju Yeol Baek, Seung-Woon Rha, Byoung Geol Choi, Yong Mo Yang, Won Ik Lee, Se Yeon Choi, Cheol Ung Choi, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
Childhood trauma doubles risk of mental health conditions
Authors: Ingrid Torjesen
Journal: BMJ (2019)

Almost a third of young people in the UK experience trauma during childhood or adolescence that doubles their risk of experiencing a range of mental health disorders, a study funded by the Medical Research Council (MRC) and published in the Lancet Psychiatry has suggested.1

The study looked at data on 2232 children born in England and Wales in 1994-95 enrolled in the Environmental Risk Longitudinal Twin Study assessed by structured interviews at the age of 18 for trauma exposure, post-traumatic stress disorder (PTSD), other psychopathology, risk events, functional impairment, and service use.

Almost a third (31.1%) had experienced trauma and one in four of these (7.8%) met the criteria …
Novel Evidence That the Ectonucleotidases CD39 and CD73, Which Are Expressed on Hematopoietic Stem/Progenitor Cells (HSPCs), Regulate Mobilization and Homing - Studies in CD39-/- and CD73-/- Mice and with Small-Molecule CD39 and CD73 Inhibitors
Authors: Mateusz Adamiak, Kamila Bujko, Anna Lenkiewicz, Magdalena Kucia, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2018)
Helen Salisbury: The perils of deprescribing
Authors: Helen Salisbury
Journal: BMJ (2019)

Imagine that my next patient is a 78 year old who’s come about her back pain—it’s no better, and she won’t get the physiotherapy she needs for many weeks yet. She’d also like me to look at a funny mole on her back. I note that she has eight medicines on her repeat prescription list and is overdue a review.

In our 12 minutes together I need to attend to her agenda but also to make sure that the cocktail of pills she’s receiving is doing her more good than harm. Alas, the discussion we’re likely to manage about each one will be along these lines: “Are you …
Abstract 1894: The lipogenic phenotype of HER2/neu-positive breast cancer cells.
Authors: Jan M. Baumann, Antonis Kourtidis, Douglas S. Conklin
Journal: Cancer Research (2013)

Abstract 15 - 30 % of all breast cancer cases are classified as HER2/neu-positive, a very aggressive form of breast cancer that correlates with a poor prognosis, reduced survival time and increased incidence of metastasis. Kourtidis et al. (2010) have recently shown that the HER2-positive breast cancer cell line BT474 relies on a unique Warburg-like metabolism for survival and aggressive behavior. These cells are dependent on fatty acid synthesis, presumably as a means to regenerate NAD+ for aerobic glycolysis. The nuclear receptors NR1D1 and PPARγ enable these cells to upregulate de novo fatty acid synthesis while avoiding palmitate-induced lipotoxicity by storing neutral fats (TAGs). The cells show markedly increased levels of stored fats compared to other breast cancer cell lines and disruption of the synthetic process results in apoptosis of BT474 cells. Metabolomic analysis of NR1D1 overexpressing cells compared to normal cells reveals profound differences in their metabolite profiles. This metabolic phenotype is operating at its limits in HER2-positive cells, as addition of exogenous palmitate results in cell death, whereas HER2-normal cells are not affected by this treatment. Microarray analysis suggests that palmitate induces an ER-stress response in the HER2-positive cells, ultimately resulting in cell death. Preliminary results suggest that this response is CHOP-dependent. Combination treatments with palmitate and HER2-targeted therapeutic compounds show synergistic effects and markedly increase the cytotoxic effects of either compound alone. The uptake of exogenous fatty acids as well as the de novo fatty acid synthesis are dependent on the essential co-factor coenzyme A (CoA), which is generated from the precursor pantothenate (vitamin B5). Based on our genomic analysis we predicted that HER2-positive breast cancer cells are more sensitive to changes in intracellular CoA levels. Our results show that HER2-positive breast cancer cells are sensitive to shRNA-mediated knockdown of coenzyme A pathway enzymes whereas MCF-7 cells are not. We observe the same pattern of sensitivity using the competitive CoA pathway inhibitor homopantothenate. Interestingly, limiting the supply of CoA in HER2-positive cells reduces the toxicity of exogenous palmitate. Our data suggest that HER2-positive breast cancer cells are metabolically different from other breast cancer cell lines and that these differences offer new possibilities for therapeutic applications. Citation Format: Jan M. Baumann, Antonis Kourtidis, Douglas S. Conklin. The lipogenic phenotype of HER2/neu-positive breast cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1894. doi:10.1158/1538-7445.AM2013-1894
Clinical highlights from the National Cancer Data Base: 1994
Authors: G. D. Steele, R. T. Osteen, D. P. Winchester, G. P. Murphy, H. R. Menck
Journal: CA A Cancer Journal for Clinicians (1994)

The National Cancer Data Base, a joint project of the American CancerSociety and the American College of Surgeons Commission on Cancer, providesa mechanism for periodic assessment of hospital-based cancer patient care.From the National Cancer Data Base's annual summary, health careprofessionals can evaluate trends in patient care to make more efficienttreatment decisions. This article provides a first look at highlights fromthe 1994 annual summary.
The liver annual 2, 1982
Authors: S. Sherlock
Journal: Gut (1982)

This is the second year of this Liver annual.Any conscientious reader of this series will certainly be kept abreast with developments in hepatology.The authors of the various sections are experts in their fields, and have been carefully chosen.Similarly, the subjects are relevant.Each essay is not simply a summary of the literature, but includes an interpretation.The present volume includes excellent contributions on hepatic protein metabolism, alcohol and the liver, viral hepatitis, and indeed all the major growing areas in hepatology.There are two problems.The review stops on 30 June 1981, so that the review of the literature is already one year out of date.The enthusiastic research worker will have to keep up with original articles in the journals.The second problem is the almost total lack of illustrative material whether tables or figures.This is presumably house policy, but makes the text much heavier going than it might be.Policy cannot be on cash grounds as the book is well up to the price asked for other better illustrated reviews.This book can be recommended to all practising hepatologists.
Abstract 2387: Characterization the role of leukocyte cell-derived chemotaxin 2 (LECT2) in angiogenesis
Authors: Chen Chi-Kuan, Wan-Chin Chung, Yu-Ling Wu, Ching-Yao Yang, Jia-Ming Chang, Ming-Lian Kuo
Journal: Cancer Research (2010)

Abstract Leukocyte Cell-Derived Chemotaxin 2 (LECT2) protein is expressed preferentially in the liver in a constitutive manner and secreted into bloodstream. Recently studies indicate that LECT2 potentially associated with the liver injury, repair, and regeneration, but other functions are still unknown. Angiogenesis is a process of new blood vessel formation which has essential roles in development, repair, tumor growth, invasion, and metastasis. In our pervious studies, we have recently identified LECT2 as a potential tumor suppressor, correlating with decreased vascular invasion in hepatocellular carcinomas (HCC). In this study, we evaluated the function of recombinant LECT2 (rLECT2) proteins on angiogenesis by using human umbilical vein endothelial cells (HUVEC). We demonstrated a selective and significant inhibition of VEGF165-induced angiogenic activity in HUVEC by rLECT2 protein through inhibiting the proliferation, migration, and tube formation. The rLECT2 protein also suppressed VEGF165-induced angiogenesis in CAM assay and matrigel plug assay. In conclusion, we for the first time found that LECT2 played an important role in anti-angiogenesis. Moreover, the LECT2 might have broad therapeutic applications in diseases characterized by excessive angiogenesis. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2387.
UTX and MBD3 Epistasis Regulates Rac Gtpase Activation and Sensitizes Human Acute Myeloid Leukemia Cells to Dock Inhibition
Authors: Shankha Subhra Chatterjee, Mayukh Biswas, Liberalis Debraj Boila, Sayan Chakraborty, Sayantani Sinha, Debasis Banerjee, Amitava Sengupta
Journal: Blood (2018)
FRI0248 Myasthenia gravis after hepatitis b vaccine. report of one case
Authors: ME Bahri, B Louzir, S Othmani, R Battikh, MO Bahri
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> <h3>Methods</h3> Myasthenia gravis (MG) is a chronic, organ-specific auto-immune disease in which anti-R-ach antibodies are considered responsible for muscle weakness. Among triggering or worsening factors, drugs were often involved. However, very little is known about the role of vaccine. Triggering MG by anti-hepatitis B vaccination was previously reported in 3 cases. We report here one new case. A 46-year old asthmatic woman without previous history of neuromuscular disorder presented in November 1995 with dyspnea, dysphonea, bilateral palpebral ptosis, difficulty of mastication and swallowing and, proximal weakness presenting at noon and with exercise, one month after second dose of plasma-derived recombinant hepatitis B vaccine (H-B-VAX II, MSD). MG was suspected and this diagnosis was confirmed by positive prostigmine test and typical electromyographic findings. Antibodies to acetylcholine receptors were not detected. The patient underwent thymectomy in Mars 1996. Then, under oral anticholinesterase therapy and corticosteroids (60 mg of prednisone daily), her condition stabilised, but her clinical status worsened when the dose of prednisone was tapered under 20 mg daily. She finally improved after institution of ciclosporine (5 mg/Kg/daily) in association with steroid therapy. <h3>Results</h3> <h3>Conclusion</h3>
Association Between In Vitro Bleeding Time and Bleeding in Preterm Infants With Thrombocytopenia
Authors: Emoke Deschmann, Matthew A. Saxonhouse, Henry A. Feldman, Mikael Norman, Maria Barbian, Martha Sola-Visner
Journal: JAMA Pediatrics (2019)

This cohort study examines the use of closure time following stimulation with collagen and adenosine diphosphate vs the platelet count as a marker of bleeding in premature neonates with thrombocytopenia.
BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
Authors: Sujan Piya, Hong Mu, Seemana Bhattacharya, Philip L. Lorenzi, R. Eric Davis, Teresa McQueen, Vivian Ruvolo, Natalia Baran, Zhiqiang Wang, Yimin Qian, Craig M. Crews, Marina Konopleva, Jo Ishizawa, M. James You, Hagop Kantarjian, Michael Andreeff, Gautam Borthakur
Journal: Journal of Clinical Investigation (2019)

The antileukemic effect of inhibiting bromodomain and extra-terminal domain-containing (BET-containing) proteins (BETPs) such as BRD4 has largely been largely attributed to transcriptional downregulation of cellular anabolic and antiapoptotic processes, but its effect on the bone marrow microenvironment, a sanctuary favoring the persistence of leukemic stem/progenitor cells, is unexplored. Sustained degradation of BETP with the small-molecule BET proteolysis-targeting chimera (PROTAC) ARV-825 resulted in a marked downregulation of surface CXCR4 and CD44, key proteins in leukemia-microenvironment interactions, in acute myeloid leukemia (AML) cells. Abrogation of surface CXCR4 expression impaired SDF-1α–directed migration and was mediated through transcriptional downregulation of PIM1 kinase, which in turn phosphorylates CXCR4 and facilitates its surface localization. Downregulation of CD44, including isoforms CD44v8–10 impaired cystine uptake, lowered intracellular reduced glutathione, and increased oxidative stress. More important, BETP degradation markedly decreased the CD34+CD38–CD90–CD45RA+ leukemic stem cell population and, alone or in combination with cytarabine, prolonged survival in a mouse model of human leukemia that included AML patient-derived xenografts (AML-PDX). Gene expression profiling and single-cell proteomics confirmed a downregulation of the gene signatures associated with "stemness" in AML and Wnt/β-catenin and Myc pathways. Hence, BETP degradation by ARV-825 simultaneously targets cell-intrinsic signaling, stromal interactions, and metabolism in AML.